Group Lifestyle Balance™ for Individuals With Stroke (GLB-CVA) — GLB-CVA  

Stroke Clinical Trial

Official title: Efficacy of an Evidence-based Healthy Lifestyle Intervention for People Following CVA

Status Active, not recruiting

Clinical Trial Summary

The purpose of this RCT is to examine the efficacy of the Group Lifestyle Balance (GLB) program adapted for people with stroke (CVA) on primary (weight) and secondary outcomes at 3, 6, 12 months from enrollment into the program.

Clinical Trial Description

Weight gain greatly increases the risk of chronic diseases after stroke such as diabetes, metabolic syndrome, pulmonary and heart disease. Approaches to weight-loss are lacking, yet necessary, due to the unique physiological and cognitive needs of persons with CVA. There is evidence that interventions that improve physical activity and healthy eating behaviors concurrently offer greatest potential for weight-loss. The Group Lifestyle Balance (GLB) intervention is a 12-month, evidence-based weight-loss program that has been used extensively with the general population, but not with people after CVA. Investigators modified the program to meet the needs of people post stroke (GLB-CVA). Study Aims: The study consists of five specific aims. Specific Aim 1: To create an appropriate adaptation of the DPP-GLB program that meets the unique needs of people post CVA (GLB-CVA) using a Community-Based Participatory Research approach and Advisory Board of key stakeholders (patients, caregivers, clinicians, researchers). Specific Aim 2: To establish the feasibility of delivering the GLB-CVA intervention. Specific Aim 3: Conduct a randomized controlled trial (RCT) to examine the effectiveness of the GLB-CVA on primary and secondary outcomes in the intervention group compared to the wait-list control group at 3, 6, and 12 months from baseline. Specific Aim 4: Describe the effect of the GLB-CVA on metabolic biomarkers in the experimental group compared to the wait-list control group at baseline, 3, and 6 months. Specific Aim 5: Describe the association between biomarkers of neurodegeneration and physiologic, functional, and patient reported outcomes at baseline, 3, and 6 months. ;

Related Conditions & MeSH terms

• Stroke

• NCT number: NCT03873467
• Study type: Interventional
• Source: Baylor Research Institute
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 8, 2019
• Completion date: December 30, 2023